The Research Sample Clauses

The Research. 2.1. In addition to the Initial Research Program, the Company may finance performance of a Subsequent Research Program in accordance with a Subsequent Research Budget during a Subsequent Research Period or any amendments thereof as may be agreed upon by the Company and Yissum following completion of the Initial Research Program. 2.2. Any Research to be conducted pursuant to the Initial Research Program shall be governed by the MOU. Any Subsequent Research Program shall be under the supervision of the Researcher. Should the Researcher be unable to complete the Research under a Subsequent Research Program for any reason, Yissum shall notify the Company of the identity of a suitable replacement researcher. If the Company does not object in writing to the replacement researcher on reasonable grounds within 20 days of this notification, the substitute researcher shall be deemed acceptable to the Company. Alternatively, the Company shall have the right to terminate any Subsequent Research Program, in which case monies paid to Yissum for the Research pursuant to the Subsequent Research Budget which have not been expended at the time of termination will be refunded to the Company; provided that the Company shall be responsible for the payment of any accrued fees and expenses due to Yissum based on work duly performed up to the date of termination and those irrevocable commitments that were part of the Subsequent Research Budget and entered into by Yissum prior to having received the Company’s written notice of termination. 2.3. For the avoidance of doubt, should the Company wish to place its employees in the laboratories of the Researcher on any campus of the University in connection with the Research or any other aspect of this Agreement it may do so after executing a separate agreement with Yissum setting out the terms of such placement; provided, however, that the Company shall have the right to have its representative visit the Researcher’s laboratories on an ad hoc, periodic basis with advanced coordination with the Researcher without the need for the execution of an agreement. 2.4. The compensation to Yissum for the performance of the Subsequent Research Program, subject to any earlier termination of the Subsequent Research Program, shall be set forth in a Subsequent Research Budget as agreed upon by Yissum and the Company. 2.5. For the avoidance of doubt, nothing herein shall prevent Yissum or the University or the Researcher from obtaining, subject to the ...

The Research. There is a significant body of research that supports the use of personal, digital learning devices in the classroom. The Horizon Report (xxxx://xxx.xxx.xxx/publications/2014-horizon-report-k12) investigates three areas of the adoption of technology in education. They include: Key Trends, Significant challenges, and Important Developments. One of the key trends that is identified in the report is a shift towards deeper learning approaches that involves “the delivery of rich core content to students in innovative ways that allow them to learn and then apply what they have learned… As technologies such as tablets and smartphones are more readily accepted in schools, educators are leveraging these tools, which students already use, to connect the curriculum with real life applications. These active learning approaches are decidedly more student-centered, allowing learners to take control of how they engage with a subject…” (p.

The Research. 2.1 In consideration of the first Work Order the Parties agree that if, during the Term, Quotient will perform any particular trial, study and/or services for the Customer, a document in substantially the form set out in Schedule 1 to this Agreement will be completed and issued by Quotient in relation to such trial, study and/or services, and will be signed by both Parties. Each such Work Order will constitute a separate contract between the Parties for the performance by Quotient and its Service Providers of the Research, and the payment by the Customer of the amounts set out in the Proposal (and the performance by the Customer of it’s other obligations), under this Agreement and the Work Order (to the exclusion of any other terms and/or conditions which the Customer may attempt or purport to impose). 2.2 Quotient and its Service Providers shall carry out all Research in accordance with the Agreement, the Work Order, relevant Clinical Protocol and with reasonable skill and care and in accordance with the Regulations appropriate to the jurisdiction where the Research is to be performed including, Good Clinical Practice, Good Manufacturing Practice, and according to all relevant ICH guidelines 2.3 Quotient must inform Customer within 2 days of any serious adverse events and significant deviations from, or breaches of the standards applied to the Services including Regulations, the Clinical Protocol and a Work Order of this Agreement, to enable Customer to meet its requirements for reporting such events to the applicable Regulatory Authority. 2.4 Quotient shall use its reasonable endeavours to carry out all Research and to deliver the Research Output in accordance with the Proposal. 2.5 All services to be provided by Quotient under this Agreement and any Work Order will be deemed provided at the Customer’s request and the Customer accepts that it is responsible for verifying that those services are suitable for its own needs. 2.6 The Customer may prior to and/or during the performance of any Work Order under this Agreement and for the requisite period thereafter, audit Quotient’s performance of any Research upon giving Quotient reasonable prior written notice. The Customer shall use its reasonable endeavours not to cause any disruption to Quotient’s business in carrying out such audit. 2.7 The Customer shall ensure that its employees co-operate fully with Quotient and any Service Providers in relation to the provision of any Research (including without limit...

The Research. 2.1 The Parties shall undertake the Allocated Work as specified in the Call Specifications and the Work Plan. The Contractor shall be bound mutatis mutandis by the terms and conditions of the Head Contract, which form part of this Subaward; except that provisions of the Head Contract that are particular to Lancaster or the Principal Investigator shall apply only to Lancaster. 2.2 The Allocated Work shall be performed by the persons named in the Work Plan, where relevant. 2.3 In respect of the Allocated Work, the Contractor will use its reasonable endeavours to provide adequate facilities; to obtain any requisite materials, equipment and personnel; and to carry out their work diligently. Although the Contractor will use its reasonable endeavours to perform the Allocated Work, the Contractor does not undertake that the Allocated Work carried out under or pursuant to this Subaward will lead to any particular result, nor is the success of such work guaranteed. 2.4 The Contractor will use reasonable endeavours to meet the milestones and deadlines set out in the Work Plan at Schedule 1, and in accordance with any Key Performance Indicators specified in the Call Specifications. In the event that there is any conflict between the Work Plan and the Call Specifications, the Call Specifications will prevail. 2.5 The Contractor will, where relevant in respect to the undertaking of the Allocated Work, in accordance with GSC ‘Dissemination and Publication of Outputs’ of the Head Contract and subject to the review requirements thereof, deposit all unclassified data sets with the UK Data Service. 2.6 The Parties will comply with all requirements of the relevant Institutional Ethics Committee in respect of the Allocated Work, and shall also refer a copy of all applications to CREST’s Security Research Ethics Committee for consideration as soon as is reasonably practical. Each Party will comply with the requirements of the Security Research Ethics Committee.

The Research. 1.1 The College’s contact for the Research shall be Xx. Xx Xxxx in its School of Genetics & Molecular Medicine (the ‘Investigator’). If Xx. Xx Xxxx is unable or unwilling to continue the supervision of the Research on behalf of the College, the College shall promptly notify the Company, and advise it of a suitable successor within 60 days thereafter; the Company shall not unreasonably decline to accept the choice of a successor selected in this way but if it can demonstrate reasonable grounds for not wishing to accept the choice, then the Company may terminate this Agreement in accordance with the terms set out in clause 8 below. 1.2 The Company’s contact for the Research shall be Xx. Xxxxx Xxxxxxx-Vives. If Xx. Xxxxx Xxxxxxx-Vives is unable or unwilling to continue the supervision of the Research on behalf of the Company, the Company shall promptly notify the College, and advise it of a suitable successor within 60 calendar days thereafter; the College shall not unreasonably decline to accept the choice of a successor selected in this way but if it can demonstrate reasonable grounds for not wishing to accept the choice, then the College may terminate this Agreement in accordance with the terms set out in clause 8 below. The parties must give notice as soon as is practicable to the other party should there be any changes to the Company or College staff so that the Research will not be negatively affected by such unforeseen changes 1.3 Each Party undertakes to supply the levels of data, manpower, materials, resources and commitment identified as its contribution to the Research in Schedule 1, and shall endeavour to ensure the accuracy of all such data and promptly to correct any error therein of which it becomes aware. For the avoidance of doubt, any data, information or materials which one Party supplies to the other in the course of the Research shall represent Confidential Information and/or Background IP (as each such term is defined elsewhere herein) belonging to that Party. The College has received funding from XXXXX U.K. for the project. The funding and budget for the Research does not include the costs of the SkinGun™, the disposable attachments, the Company’s expertise and assistance in anything related to the cell delivery. The College does not have any publishing, patent, or intellectual property obligations to XXXXX U.K. which may affect this Research. 1.4 If either Party reasonably believes that the Research or the way in which a Party is under...

The Research. 1.1 Yissum, through the Faculty of Science of The Hebrew University of Jerusalem (“HUJI” or the “University”), shall perform certain research during the Research Period (as defined below), employing the services of the Researcher (as defined below), all strictly in accordance with the details, objectives and specifications of the protocol attached hereto as Appendix A (and as may be amended from time to time by the Parties) (the “Research” and the “Research Protocol”, respectively).

The Research. 2.1 The Company undertakes to fund and pursue the Initial Research in accordance with the terms contained herein, and to make its reasonable commercial efforts to actively pursue the performance of the Research, and to secure funding for the Research. The parties hereto acknowledge that the administration of the Company’s research and development activities in Israel shall be performed by Biogal Israel, as a sublicensee of the Company, pursuant to the terms and conditions of the Sublicense Agreement executed concurrently with this Agreement by and between the Company and Biogal Israel, attached hereto as Attachment E. The Parties hereto acknowledge that the financing of the Company’s research and development activities in Israel shall be performed by the Company and that the Company and Biogal Israel shall be jointly and severally liable for such financing. The Initial Research shall be performed at the Institute and certain hospitals and medical institutes as set forth in the Initial Research Program, and within the framework of the Initial Research Budget. The Initial Research Budget with regard to the Research at the Institute shall consist of one thirteen (13) month period and payments for the performance of the Research at the Institute shall be made in four installments, as follows (i) for the first nine-month period of the Initial Research, payment shall be made for each three month period in advance; and (ii) for the last four month period of the Initial Research, payment shall be made in one installment in advance. The Initial Research Budget with regard to the Initial Clinical Research shall consist of one eighteen (18) month period, and payments for the performance of the Initial Research Budget shall be made for each three (3) month period in advance. 2.2 Subject to the terms and conditions hereof, Yeda undertakes to procure the performance of the laboratory portion of the Initial Research designated to be performed at the Institute according to the Initial Research Program (the “Research at the Institute”), under the supervision of Pxxx. Xxxxx-Xxxxx provided however that the fact that Pxxx. Xxxxx-Xxxxx shall cease to be available for the supervision of the performance of the Research at the Institute shall not constitute a breach of this Agreement by Yeda. In such event, Yeda shall make its reasonable effort to find from amongst the scientists of the Institute a replacement scientist acceptable to the Company (such acceptance to be in writing,...

The Research. 2.1. The Company hereby undertakes to finance performance of the Research in accordance with the Research Program or any amendment thereof. Such financing shall be, subject to any earlier termination of the Research pursuant to Section 2.2 below, in an amount of at least New Israeli Shekels [NIS ] (inclusive/exclusive?? of overhead) (the “Research Fee”) plus value added tax (VAT), if applicable, payable in accordance with the Research Budget as set forth in Appendix A. Because the allocation of expenses in the Research Budget is based on expected expense categories and an expected allocation of specific expenses within each category, such categories and the allocation of expenses among the various expense categories may be modified by the Researcher(s) where reasonably necessary or appropriate during the Research Period, it being agreed, however that the aggregate Research Fee shall not be increased without the written consent of the Company. Payments may be made by check or by wire transfer to the following account: Name of Bank: Hapoalim Bank Key: 12 Bank's Address: Xxxxxxxx 00, Xxxxx, Xxxxxx Branch: Holon Service Center - 436 Bank Account Number: 12-436-142-155001 Swift Code: XXXXXXXX IBAN: XX00-0000-0000-0000-0000-000 (if required for payment from any country) The Company shall always use the payment information provided above. The Company shall not accept any changes in respect of the payment route or bank account details that are received via email, facsimile or by other means of communication, including, without limitation, any invoice or other written request for payment, unless such changes are set forth in an amendment to this Agreement on the letterhead of Yissum signed by its Chief Financial Officer or Controller. If the Company breaches this provision, it shall bear any financial loss or other consequences arising therefrom and shall indemnify Yissum for any such loss or damages that may be incurred by Xxxxxx. 2.2. The Research shall be conducted by and under the supervision of the Researcher. Should the Researcher be unable to complete the Research for any reason, Xxxxxx shall notify the Company of the identity of a suitable replacement researcher. If the Company does not object in writing to the replacement of a researcher on reasonable grounds within twenty (20) days of this notification, the substitute researcher shall be deemed acceptable to the Company. Alternatively, the Company shall have the right to terminate the Research being condu...

The Research. 3.1 It is agreed between the Parties that the Research will be conducted by Xx. Xxxx Angel, of the Institute of Biologické centrum AV CR, v. v. i. ("the Researcher") who has the knowledge, the skills and the experience required to perform the Research under the conditions as set forth herein. 3.2 The description of the Research is detailed in Appendix A, attached hereto as an integral part of the Agreement.

The Research. A. DepoMed agrees to use its diligent efforts to implement and complete the Research Plan attached herewith and fully incorporated herein as Appendix A. Elements of this plan may be modified, but only by mutual written agreement of PRI and DepoMed (the "Parties") at any time during the term of this Agreement. B. PRI agrees to collaborate with and assist DepoMed in the implementation and completion of the Research Plan set forth in Appendix A by providing to DepoMed: 1. Bulk [* *] in sufficient quantities to perform the Research Plan; 2. Appropriate analytical and handling procedures for [* *]; and CONFIDENTIAL TREATMENT REQUESTED THE SYMBOL "[* *]" IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 3. Such other technology and expertise possessed by PRI which may be deemed necessary, by subsequent mutual agreement of the Parties, to achieve the objectives of this Agreement. C. All [* *], including work in process, shall remain the sole property of PRI. DepoMed agrees not to make any modifications of the [* *] provided by PRI hereunder, except as required in the performance of the Research Plan. D. The [* *] shall be used solely to conduct the Research Plan, and not for any other purpose. The [* *] shall not be made available to anyone other than employees of DepoMed working in furtherance of the Research Plan, shall not be transferred to any other persons outside of DepoMed for any purpose, and shall not be transferred to another institution or company without the prior written consent of PRI.